



## 2021 Virtual Congress – Scientific Program

All program timing in CET

Day 1, Friday, May 7 <sup>th</sup>	
<b>12:00-13:15</b>	<b>Industry or non-profit symposium</b>
<b>13:15-13:30</b>	<b>Welcome by Congress chairs</b>
<b>13:30-15:00</b>	<b>Session 1: High risk disease biology</b>
13:30-13:45	Disease risk scoring <b><u>Hervé Avet-Loiseau, France</u></b>
13:45-14:00	Genomics of high-risk myeloma <b>TBA</b>
14:00-14:15	IMiDs resistance pathways <b><u>Keith Stewart, Canada</u></b>
14:15-15:00	Round table debate <i>Speakers and,</i> <b><u>Gordon Cook, UK</u></b> <b><u>Gareth Morgan, USA</u></b>
<b>15:00-16:30</b>	<b>Session 2: Immune deregulation in myeloma</b>
15:00-15:15	Role of the microenvironment <b><u>Irene Ghobrial, USA</u></b>
15:15-15:30	Mechanisms of resistance to immunotherapy <b><u>Niels van de Donk, Netherlands</u></b>
15:30-15:45	Strategies to reverse immune deregulation in myeloma <b><u>Paola Neri, Canada</u></b>
15:45-16:30	Round table debate <i>Speakers and,</i> <b><u>Bertrand Arnulf, France</u></b> <b><u>Marc Raab, Germany</u></b>
<b>16:30-18:00</b>	<b>Plenary satellite symposium</b>
<b>18:00-19:15</b>	<b>Session 3: Plenary lectures</b>
18:00-18:25	Therapy of AL amyloidosis: an update <b><u>Giampaolo Merlini, Italy</u></b>
18:25-18:50	Therapy of Waldenstrom macroglobulinemia <b><u>Steve Treon, USA</u></b>
18:50-19:15	Round table debate <i>Speakers and,</i> <b><u>Jorge Castillo, USA</u></b>
<b>19:15-20:30</b>	<b>Industry or non-profit symposium</b>



<b>Day 2, Saturday, May 8<sup>th</sup></b>	
<b>10:00-11:00</b>	<b>Session 4: Snapshot talks (part 1) - Latest data</b>
10:00-10:10	Latest data on HDAC inhibitors <b><u>Enrique Ocio, Spain</u></b>
10:10-10:20	Latest data on Targeting SLAMF7 <b><u>Katia Weisel, Germany</u></b>
10:20-10:30	Latest data on targeting Bcl2 inhibitors <b>TBA</b>
10:30-10:40	Latest data on biphosphonates <b><u>Evangelos Terpos, Greece</u></b>
10:40-10:50	Latest data on antibody drug conjugates <b><u>Suzan Trudel, Canada</u></b>
10:50-11:00	Latest data in POEMS <b><u>Artur Jurczynszyn, Poland</u></b>
<b>11:00-12:30</b>	<b>Session 5: Snapshot talks (part 2) - Clinical trials updates</b>
11:00-11:10	IFM 2009 <b><u>Aurore Perrot, France</u></b>
11:10-11:20	Carfilzomib, lenalidomide, and dexamethasone plus transplant <b><u>Andrzej Jakubowiak, USA</u></b>
11:20-11:30	GRIFFIN <b><u>Jonathan Kaufman, USA</u></b>
11:30-11:40	MASTER <b><u>Luciano Costa, USA</u></b>
11:40-11:50	IKEMA <b><u>Tom Martin, USA</u></b>
11:50-12:00	CANDOR <b><u>Saad Usmani, USA</u></b>
12:00-12:30	Q&A
<b>12:30-13:30</b>	<b><i>Industry symposium</i></b>
<b>13:30-14:45</b>	<b>Session 6: Therapy of young patients</b>
13:30-13:45	The optimal induction regimen <b><u>Philippe Moreau, France</u></b>
13:45-14:00	Role of consolidation (including double auto-transplant) <b><u>Michele Cavo, Italy</u></b>
14:00-14:15	Maintenance approaches post-transplant <b><u>Francesca Gay, Italy</u></b>
14:15-14:45	Round table debate <i>Speakers and,</i> <b><u>Peter Sonneveld, Netherlands</u></b> <b><u>Joan Blade, Spain</u></b> <b><u>Muzaffar Qazilbash, USA</u></b>



<b>14:45-16:00</b>	<b>Session 7: Therapy of elderly patients</b>
14:45-15:00	IMiD-based approaches <b><u>Thierry Facon, France</u></b>
15:00-15:15	Proteasome-based approaches <b><u>Marivi Mateos, Spain</u></b>
15:15-15:30	Personalized treatment of the elderly TBA
15:30-16:00	Round table debate <i>Speakers and,</i> <b><u>Alessandra Larocca, Italy</u></b> <b><u>Meral Beksac, Turkey</u></b>
<b>16:00-17:30</b>	<b><i>Plenary satellite symposium</i></b>
<b>17:30-18:30</b>	<b>Session 8: Therapy of smoldering myeloma – a debate</b>
17:30-17:45	Pro <b><u>S. Vincent Rajkumar, USA</u></b>
17:45-18:00	Con <b><u>Xavier Leleu, France</u></b>
18:00-18:30	Round table debate <i>Speakers and,</i> <b><u>Shaji Kumar, USA</u></b> <b><u>Aurore Perrot, France</u></b> <b><u>Rafat Abonour, USA</u></b>
<b>18:30-19:45</b>	<b>Session 9: Plenary lectures</b>
18:30-18:55	MRD-based therapy: hope, hype, or reality? <b><u>Jesus San Miguel, Spain</u></b>
18:55-19:20	How to extend survival at relapse? <b><u>Meletios Dimopoulous, Greece</u></b>
19:20-19:45	Round table debate <i>Speakers and,</i> <b><u>Jean-Luc Harousseau, France</u></b> <b><u>Nizar Bahlis, Canada</u></b> <b><u>Kwee Yong, UK</u></b> <b><u>Saad Usmani, USA</u></b>
<b>19:45-20:45</b>	<b><i>Industry or non-profit symposium</i></b>



<b>Day 3, Sunday, May 9<sup>th</sup></b>	
<b>10:00-11:00</b>	<b>ORAL PRESENTATIONS</b>
<b>11:00-12:20</b>	<b>Session 10: Snapshot talks - Practical considerations</b>
11:00-11:10	Practical considerations when using anti-CD38 antibodies <b>TBA</b>
11:10-11:20	Management of cardiovascular adverse events <b>Inger Nijhof, Netherlands</b>
11:20-11:30	MRD monitoring: when, how and in which patient? <b>Bruno Paiva, Spain</b>
11:30-11:40	MGUS diagnosis: a step by step approach <b>Graham Jackson, UK</b>
11:40-11:50	Imaging: the essential work-up <b>Elena Zamagni, Italy</b>
11:50-12:00	COVID-19 vaccination in myeloma <b>Heinz Ludwig, Austria</b>
12:00-12:20	Q&A
<b>12:20-13:30</b>	<b><i>Industry or non-profit symposium</i></b>
<b>13:30-14:30</b>	<b>Session 11: Bispecific antibodies forum</b>
13:30-13:45	The case for BCMA as a target <b>Alfred Garfall, USA</b>
13:45-14:00	The case for non-BCMA targets <b>Ajai Chari, USA</b>
14:00-14:30	Round table debate <i>Speakers and,</i> <b>Adam Cohen, USA</b> <b>Hermann Einsele, Germany</b> <b>Luciano Costa, USA</b> <b>Suzanne Lentzsch, USA</b>
<b>14:30-15:30</b>	<b>Session 12: CAR-T cells forum</b>
14:30-14:45	The case for Ide-Cel <b>Noopur Raje, USA</b>
14:45-15:00	The case for Cilta-Cel <b>Deepu Madduri, USA</b>
15:00-15:30	Round table debate <i>Speakers and,</i> <b>Nina Shah, USA</b> <b>Arnon Nagler, Israel</b> <b>Salomon Manier, France</b> <b>Caitlin Costello, USA</b>



<b>15:30-16:30</b>	<b>Session 13: Novel drugs forum</b>
15:30-15:40	Melflufen-based combinations <b><u>Paul Richardson, USA</u></b>
15:40-15:50	Iberdomide-based combinations <b><u>Sagar Lonial, USA</u></b>
15:50-16:00	<i>TBA</i>
16:00-16:30	Round table debate <i>Speakers and,</i> <i>TBA</i>
<b>16:30-18:00</b>	<b><i>Plenary satellite symposium</i></b>
<b>18:00-18:30</b>	<b>Session 14: Plenary lecture</b>
18:00-18:30	Multiple myeloma in 2025: the next steps? <b><u>Kenneth Anderson, USA</u></b>
<b>18:30-19:00</b>	<b>Awards Ceremony</b>